Investors

Press Releases

Date Title View
Toggle Summary Momenta Pharmaceuticals Reports Second Quarter 2019 Financial and Operating Results
— Launches adaptive Phase 2/3 study of nipocalimab (M281) in Warm Autoimmune Hemolytic Anemia (wAIHA), the Company’s third study of its FcRn inhibitor; top-line data expected by end of 2021 — — Company receives FDA Fast Track Designation for nipocalimab in wAIHA and HDFN — CAMBRIDGE, Mass. , Aug.
View HTML
Toggle Summary Momenta Pharmaceuticals Launches Phase 2/3 Trial of M281 for the Treatment of Warm Autoimmune Hemolytic Anemia and is Granted FDA Fast Track Designation
CAMBRIDGE, Mass. , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, announced the launch of an adaptive Phase 2/3 clinical study for its
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Fast Track Designation for M281 (nipocalimab) in Hemolytic Disease of the Fetus and Newborn (HDFN)
CAMBRIDGE, Mass. , July 30, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that the U.S.
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Date of Second Quarter 2019 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass. , July 19, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results for the
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Settlement Agreement with Amphastar Resolving Enoxaparin Sodium Injection Litigation
CAMBRIDGE, Mass. , June 19, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that Momenta, Sandoz AG and Amphastar Pharmaceuticals
View HTML
Toggle Summary Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 40th Annual Global Healthcare Conference
CAMBRIDGE, Mass. , June 04, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that Craig Wheeler , President and CEO, will present
View HTML
Toggle Summary Momenta Pharmaceuticals to Webcast Presentation at the 2019 Bank of America Merrill Lynch Healthcare Conference
CAMBRIDGE, Mass. , May 09, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that Craig Wheeler , President and CEO, will present at
View HTML
Toggle Summary Momenta Pharmaceuticals Reports First Quarter 2019 Financial and Operating Results
— M281 Phase 2 trials in MG and HDFN active and enrolling patients — — Data supporting M281’s mechanism in HDFN, as first anti-FcRn antibody to inhibit maternal-fetal IgG transfer in perfusion model of the human term placenta, published in American Journal of Obstetrics & Gynecology — — First
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Date of First Quarter 2019 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass. , April 18, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results for the
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2019
- Data highlight potential of Fc multimerization technology platform to significantly enhance the potency and efficacy of therapeutic antibodies - CAMBRIDGE, Mass. , March 28, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and
View HTML